Vaccine Plant for J&J to Stay on Hold After FDA Inspection (2)

April 21, 2021, 4:04 PM

Production at an Emergent BioSolutions Inc. facility in Baltimore that’s expected to help make Johnson & Johnson’s coronavirus vaccine will remain on hold, U.S. regulators said, after an inspection turned up multiple problems.

The U.S. Food and Drug Administration said in a report posted on its website Wednesday that Emergent failed to thoroughly investigate unexplained discrepancies, including the cross-contamination of a vaccine substance batch with ingredients from another shot.

Emergent’s facility also lacked sufficient oversight and conditions were unsanitary, the agency said. Output at the plant has been on hold amid the inspection, which began last week and concluded ...

To read the full article log in.

Learn more about a Bloomberg Law subscription